Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

NCT01082068
completedphase_1

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

NCT00485719
completedphase_1

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

NCT00704080
completedphase_1

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

NCT01240460
completedphase_1

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

NCT00777699

Clinical Trials (5)

Showing 5 of 5 trials
NCT01082068Phase 1

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Completed
NCT00485719Phase 1

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

Completed
NCT00704080Phase 1

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Completed
NCT01240460Phase 1

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

Completed
NCT00777699Phase 1

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5